• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Athersys Inc. (Amendment)

    2/9/22 3:24:54 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email
    SC 13G/A 1 tv0333-athersysinc.htm SCHEDULE 13G/A athersysinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Athersys Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  04744L106

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  04744L106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    323,091

    7.  SOLE DISPOSITIVE POWER

    9,670,898

    8.  SHARED DISPOSITIVE POWER

    405,546

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,076,444

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.28%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Athersys Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3201 Carnegie Avenue
    Cleveland, OH 44115-2634

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    04744L106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $ATHX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHX

    DatePrice TargetRatingAnalyst
    11/19/2021$1.25Buy → Neutral
    B of A Securities
    11/19/2021Buy → Neutral
    BofA Securities
    More analyst ratings

    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athersys downgraded by B of A Securities with a new price target

      B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25

      11/19/21 8:21:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys downgraded by BofA Securities

      BofA Securities downgraded Athersys from Buy to Neutral

      11/19/21 7:12:53 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hansen Maia covered exercise/tax liability with 67 shares, decreasing direct ownership by 0.10% to 70,010 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      12/21/23 11:37:15 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hansen Maia covered exercise/tax liability with 23,149 shares, decreasing direct ownership by 25% to 70,144 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      10/6/23 5:34:28 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Camardo Daniel A. covered exercise/tax liability with 19,993 shares, decreasing direct ownership by 7% to 285,341 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      10/6/23 5:28:22 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    SEC Filings

    See more
    • Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      1/8/24 7:31:19 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Athersys Inc.

      25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)

      12/27/23 9:01:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      12/22/23 5:09:11 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

      Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.

      11/16/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

      Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants

      10/16/23 4:52:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

      The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s

      10/10/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Athersys Inc.

      SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)

      7/8/22 4:57:01 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Athersys Inc. (Amendment)

      SC 13G/A - ATHERSYS, INC / NEW (0001368148) (Subject)

      2/9/22 3:24:54 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Athersys, Inc. (Amendment)

      SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)

      9/21/21 9:14:13 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

      Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t

      8/11/23 8:00:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

      Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V

      2/2/23 5:25:00 PM ET
      $ATHX
      $IMMR
      $NNDM
      $SSYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer peripheral equipment
      Technology
    • Athersys Appoints Joseph Nolan to Its Board of Directors

      Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th

      1/5/23 4:33:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Financials

    Live finance-specific insights

    See more
    • Athersys to Host Business Update Conference Call on August 9th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date

      7/31/23 1:38:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys to Host Business Update Conference Call on April 20th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time

      4/10/23 3:29:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys to Host Business Update Conference Call on February 14th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re

      2/2/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care